COCONUT CREEK, FLORIDA - EQS - NutraLife Biosciences,
Inc. ("the Company" or "NutraLife") (OTCQB: NLBS) has
received two licenses from the Wisconsin Department of Agriculture to grow and
process industrial hemp within the state. The Company plans to develop
efficient, cost reducing growing systems and processing technologies for
Edgar Ward, Founder and CEO of
NutraLife, commented: "As a company entering the bio-life sciences space
it is our goal to become vertically integrated as a trusted supplier of raw
bulk materials and insure the efficacy and quality of the products
According to a recent Hemp Industry Daily report, Wisconsin was deemed a 'new and
emerging market' for hemp and hemp production. The report also names Wisconsin
the 'fastest-moving state yet to allow hemp industry to take root.' Other up
and coming states include California and Virginia, to name a few.
The Company's in-house products
include the NutraHempCBD and
NutraSpray brands. The Company manufactures 100% of its in-house products at
its FDA approved facility in accordance with GMP. The Company developed its
first branded products in 2013. The Company's product development, testing and
research is conducted by four chemists under the supervision of Mr. Ward.
NutraLife Biosciences, Inc.,
formerly known as NutraFuels, Inc., ("NutraLife" or the
"Company") also recently announced a name change to NutraLife
BioSciences, Inc. and new stock trading symbol, NLBS. The Company believes that
the name, NutraLife BioSciences better reflects its current and planned future
The Company is a fully
reporting company with a class of securities registered with the U.S.
Securities and Exchange Commission ("SEC"). The Company recently
announced its financial results for the three (3) and nine (9) month period
ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively
compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period
ended September 30, 2017. NTFU's filings with the SEC can be viewed at www.sec.gov. NTFU's CBD products
and information about the company's direct sales program can be found online at www.nutrahempcbd.com and by following the company
* These statements have not
been evaluated by the Food and Drug Administration.
* This product is not intended
to diagnose, treat, cure or prevent any disease.
This communication contains statements of a forward-looking nature about
NutraLife BioSciences, Inc., (the "Company"). These statements are
made under the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. You can identify these
forward-looking statements by words or phrases such as "may,"
"will," "except," "anticipate," "aim,"
"estimate," "intend," "plan,"
"believe," "is/are likely to," "future" or other
similar expressions. The Company has based these forward-looking statements
largely on the Company's current expectations and projections about future
events and financial trends that the Company believes may affect Company's
financial condition, results of operations, business strategy, and financial
needs. There is no assurance that the Company's current expectations and
projections are accurate. All forward-looking statements in this press release
are based on information available to the Company on the date hereof. These
statements involve known and unknown risks, uncertainties and other factors
that may cause the Company's actual results to differ materially from those
implied by the forward-looking statements. More detailed information about
these risk factors are set forth in the Company's filings with the Securities
and Exchange Commission, including, but not limited to, those risks and
uncertainties listed in the section entitled "Risk Factors," in the
Company's Annual Report on Form 10-K with the Securities and Exchange
Commission on April 17, 2018. The Company operates in a rapidly evolving
environment. New risk factors emerge from time to time, and it is impossible
for the Company's management to predict all risk factors, nor can the Company
assess the impact of all factors on Company's business or the extent to which
any factor, or combination of factors, may cause actual results to differ from
those contained in any forward-looking statement. The Company does not
undertake any obligation to update or revise the forward-looking statements
except as required under applicable law.